Experts Clash over Whether the Pharmaceutical Industry Can Regulate Itself

摘要

The topic was Self Regulation in the Pharmaceutical Industry - What can it achieve? The answers were as diverse as the delegates who participated in a meeting organised by the Basel Institute on Governance in Basel, Switzerland on 21 April 2005. To Novartis, self-regulation was a form of enlightened self-interest. This was illustrated by the company's decision to set up an institute in Singapore to work on new therapies for dengue fever and tuberculosis. But to Marcia Angell, the former New England Journal of Medicine editor, self-regulation was a concept that had failed.